Leukemia Recurrent | Leukemia refractory | Standard therapy Remission Durable | Myelodysplasia Low Risk | Refractory anaemia with excess blasts | Refractory anemia with excess blasts II | Leukemia, Myelomonocytic, Chronic | Acute Myelocytic Leukemia WHO tumor classification | Acute lymphocytic leukemia | Chronic Lymphocytic Leukemia | Blast Phase | Primary Myelofibrosis
Item
patients must have relapsed/refractory leukemias for which no standard therapies are anticipated to result in a durable remission. patients with poor-risk myelodysplasia (mds) [i.e. refractory anemia with excess blasts (raeb-1 or raeb-2) by who classification] and chronic myelomonocytic leukemia (cmml) are also candidates for this protocol. relapsed/refractory leukemias include acute non-lymphocytic leukemia (aml) by who classification, acute lymphocytic leukemia (all), chronic lymphocytic leukemia (cll), or chronic myelogenous leukemia (cml) in blast crisis. patients with agnogenic myeloid metaplasia (amm) are also eligible.
boolean
C0023418 (UMLS CUI [1,1])
C2945760 (UMLS CUI [1,2])
C0023418 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
C2936643 (UMLS CUI [3,1])
C0544452 (UMLS CUI [3,2])
C0449238 (UMLS CUI [3,3])
C0026985 (UMLS CUI [4,1])
C3538919 (UMLS CUI [4,2])
C0002894 (UMLS CUI [5])
C1318551 (UMLS CUI [6])
C0023480 (UMLS CUI [7])
C0023467 (UMLS CUI [8,1])
C1301142 (UMLS CUI [8,2])
C0023449 (UMLS CUI [9])
C0023434 (UMLS CUI [10])
C0005699 (UMLS CUI [11])
C0001815 (UMLS CUI [12])
ECOG performance status
Item
ecog performance status of 0-2
boolean
C1520224 (UMLS CUI [1])
Sexually active Contraceptive methods | Female Sterilization | Postmenopausal state | Male sterilization | Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative | Premenopausal state
Item
sexually active men and women who are not surgically sterile or post menopausal must use acceptable contraceptive methods (physician will discuss acceptable methods) during the time on study and for 4 weeks following the completion of treatment. women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this trial.
boolean
C0241028 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0015787 (UMLS CUI [2])
C0232970 (UMLS CUI [3])
C0024559 (UMLS CUI [4])
C3831118 (UMLS CUI [5,1])
C0430061 (UMLS CUI [5,2])
C3831118 (UMLS CUI [6,1])
C0430057 (UMLS CUI [6,2])
C0232969 (UMLS CUI [7])
Disease Rapidly progressive Absent | Cytotoxic agent | Non-Cytotoxic Agent | Chemotherapy | Toxicity chronic persistent CTCAE Grades
Item
in the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents, or at least five half-lives for noncytotoxic agents. persistent chronic toxicities from prior chemotherapy must not be greater than grade 1.
boolean
C0012634 (UMLS CUI [1,1])
C1838681 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0304497 (UMLS CUI [2])
C2827065 (UMLS CUI [3])
C0392920 (UMLS CUI [4])
C0600688 (UMLS CUI [5,1])
C0205191 (UMLS CUI [5,2])
C0205322 (UMLS CUI [5,3])
C1516728 (UMLS CUI [5,4])
Laboratory Results
Item
patients must have the following clinical laboratory values:
boolean
C1254595 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine: <= 2.0 mg/dl
boolean
C0201976 (UMLS CUI [1])
Serum total bilirubin measurement | Serum total bilirubin measurement Due to Gilbert Disease
Item
total bilirubin: <=1.5x the upper limit of normal unless considered due to gilbert's syndrome
boolean
C1278039 (UMLS CUI [1])
C1278039 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0017551 (UMLS CUI [2,3])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement Due to Organ involvement Leukemia | Aspartate aminotransferase measurement Due to Organ involvement Leukemia
Item
alanine aminotransferase (alt), or aspartate aminotransferase (ast): <= 3x the upper limit of normal unless considered due to organ leukemic involvement
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0457576 (UMLS CUI [3,3])
C0023418 (UMLS CUI [3,4])
C0201899 (UMLS CUI [4,1])
C0678226 (UMLS CUI [4,2])
C0457576 (UMLS CUI [4,3])
C0023418 (UMLS CUI [4,4])
Informed Consent
Item
must be able and willing to give written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age equal to or greater than 18 years
boolean
C0001779 (UMLS CUI [1])
Comorbidity Uncontrolled | Communicable Disease Uncontrolled | Symptomatic congestive heart failure | Cardiac Arrhythmia | Mental disorder Protocol Compliance Limited | Social situation Protocol Compliance Limited
Item
uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0742758 (UMLS CUI [3])
C0003811 (UMLS CUI [4])
C0004936 (UMLS CUI [5,1])
C0525058 (UMLS CUI [5,2])
C0439801 (UMLS CUI [5,3])
C0748872 (UMLS CUI [6,1])
C0525058 (UMLS CUI [6,2])
C0439801 (UMLS CUI [6,3])
Heart Disease | Myocardial Infarction | Coronary Artery Disease Symptomatic | Cardiac Arrhythmia Uncontrolled | Congestive heart failure Uncontrolled
Item
active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure
boolean
C0018799 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C1956346 (UMLS CUI [3,1])
C0231220 (UMLS CUI [3,2])
C0003811 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0018802 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
Hyperreactive airway disease Severe | Asthma | Chronic Obstructive Airway Disease
Item
patients with a history of severe hyper-reactive airway system (e.g. active asthma, copd)
boolean
C0340062 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0004096 (UMLS CUI [2])
C0024117 (UMLS CUI [3])
Standard therapy Hematologic Neoplasm | Investigational Therapy Hematologic Neoplasm
Item
patients receiving any other standard or investigational treatment for their hematologic malignancy
boolean
C2936643 (UMLS CUI [1,1])
C0376545 (UMLS CUI [1,2])
C0949266 (UMLS CUI [2,1])
C0376545 (UMLS CUI [2,2])
Pregnancy | Breast Feeding | perifosine
Item
pregnant and nursing patients are excluded because the effects of perifosine on a fetus or nursing child are unknown.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0754570 (UMLS CUI [3])